



National Institute for Public Health  
and the Environment  
*Ministry of Health, Welfare and Sport*

# Enhancing biosecurity on pig farms and freezing meat to prevent toxoplasmosis

A Social Cost-Benefit Analysis



National Institute for Public Health  
and the Environment  
*Ministry of Health, Welfare and Sport*

## Contents

1. Economic evaluations
2. Prevention of toxoplasmosis
3. Two interventions
4. Design of the SCBA
5. Data needed
6. Stakeholders involved
7. Results
8. Conclusion



# National Institute for Public Health and the Environment



RIVM –  
Committed to health  
and sustainability



# National Institute for Public Health and the Environment



Governmental research and knowledge institute

providing policy support to (a.o)

- Dutch Ministry of Health, Welfare and Sport;
- Ministry of Housing, Spatial Planning and the Environment;
- Ministry of Agriculture Nature and Food Quality;
- National Food Authority, and several National Inspectorates.
- EU bodies



## RIVM: 3 main fields of interest

1. Centre for Infectious diseases control
2. Environment and Safety
3. Public Health and Health Services

- o ~1700 staff employed

Toxoplasmosis project here presented is collaboration of:

- o Centre for Zoonoses and Environmental Microbiology
- o Centre for Nutrition, Prevention and Health Services
- o Centre for Infectious Diseases Epidemiology and Surveillance



## Economic evaluation at the RIVM

- 10 health and environmental economists, wider group of about 30 people with economic interests
  
- Longstanding tradition of economic evaluation for public health interventions, some classical examples:
  - Vaccination
  - National screening campaigns, i.e. hepatitis screening
  - Interventions targeted at (more) healthy living:
    - Stop smoking
    - Enhance physical activity
    - More healthy nutrition
    - Alcohol use



## Economic evaluation: background

Always involves a comparative analysis of two or more alternative investment possibilities (incremental cost effectiveness analysis).


Goal is to systematically:

- identify,
- measure,
- value, and
- compare
- costs and benefits (consequences) of different alternative
- interventions (investments)





## Economic evaluation




Comparator 0 = Current program / intervention





# Economic evaluation

**NOT: Is this intervention cheaper than other interventions**





## Cost-effectiveness analysis (CEA) most often used

- Ratio of cost differences over effect differences:

Cost-utility ratio of B (intervention under study) compared to A (reference situation – old situation):

$$\frac{\text{net cost B} - \text{net cost A}}{\text{QALYs B} - \text{QALYs A}}$$


Net cost: Cost of intervention -/- future savings

The cost-utility ration expresses the amount of money needed (and will not be available for alternative options anymore) to achieve one additional **Quality Adjusted Life Year (QALY)**, if we replace the reference situation (A) with the intervention under study (B)




# Quality adjusted life year (QALY) as outcome measure

QALY = one life year in full quality






# Cost-effectiveness plane





# Cost-effectiveness plane





## WTP for QALY international

| Country         | Currency | Threshold local currency | Threshold in Euro |
|-----------------|----------|--------------------------|-------------------|
| US              | USD      | 50000-100000             | 36.600-73.200     |
| Sweden          | SEK      | 500000                   | 54.000            |
| UK              | GBP      | 30000                    | 44.500            |
| Australia       | AUSD     | 42000-76000              | 26.200-47.400     |
| Canada          | CND      | 20000-100000             | 13.700-68.700     |
| The Netherlands | EURO     | 20000-80.000             | 20.000-80.000     |
| New Zealand     | NZD      | 20000                    | 11.200            |

World Bank: QALY may cost up to 3 times GDP per capita, if  $\leq 1$  GDP/capita, intervention is very cost-effective  
Dutch GDP ~ €35.000 per capita



## Economic evaluation - perspective

- Perspective: the viewpoint from which an economic evaluation is conducted, determines which costs to include and how effects are valued
- Two perspectives most often used in health economic evaluations:
  - Health care perspective: include health care costs and health effects only (third party payer perspective / insurance perspective / Ministry of Health)
  - Societal perspective: Include ALL COSTS and ALL BENEFITS regardless who incurs costs and who obtains benefits



## Main features of Social Cost-Benefit Analysis

- Policy options are compared based on their consequences for welfare levels for society at large
- All costs and all effects are expressed in monetary terms, including health effects, death, pain, suffering
- Starting point is an inventory of all societal effects of interventions: healthcare, criminal justice, school system, production losses, traffic accidents, companies, etc etc.
- A positive net benefit implies that the intervention has more benefits than costs, and vice versa





## Some additional features of SCBA (2)?

SCBA is a cumulation of:

- “soft” Euro’s (hypothetical, non-financial Euro’s, e.g. monetary value of health effects)
- “real” Euro’s (real money, e.g. savings as a consequence of less hospitalisation)
- This implies that the net benefit is not similar to money that can be readily spent
- Effects that cannot be quantified will return as a PM (Pro Memori) in the SCBA



## In sum


Economic evaluations are important for policy making

Social Cost-Benefit Analyses are preferred when more sectors of society are involved






# Toxoplasmosis





# Disease burden (DALYs) in the Netherlands

|            | 2012 | 2016 |
|------------|------|------|
| Congenital | 2151 | 1622 |
| Acquired   | 1345 | 280  |
| Total      | 3496 | 1902 |





## Prevention of toxoplasmosis

- High burden among foodborne diseases: effective and cost-effective preventive interventions are warranted
- It is essential to determine the extent and dimensions of the problem, possible effective interventions and the costs and benefits of implementing those for society
- Freezing meat intended for raw or undercooked consumption, and enhancing biosecurity on pig farms are promising interventions to prevent *T. gondii* infections in humans
- Implementing these interventions would expectedly reduce the number of infections; the net benefits for society are unknown.




## Two hypothetical interventions

1. Enhancing biosecurity on pig farms



2. Freezing meat intended for raw or undercooked consumption



- Assumption: implementation within EU (with no additional advantages or disadvantages for countries)



# Freezing meat intervention

Targeted at:

- Steak tartare also known as filet américain
- Steak
- Lamb chop
- Leg of mutton





## Biosecurity intervention

Quality assurance and monitoring working procedures on pig farms is already established in the Netherlands

In this SCBA we assess:

- A practical risk based surveillance program
- Identification of seropositive pig farms by blood samples taken at slaughter
- An additional audit on positive farms for the presence of risk factors and recommendations how to control these risk factors (e.g. measures to exclude cats from stables, storage of feed, control of rodents)






## Design of the SCBA model

Information of costs, benefits and stakeholders from several sources and models is needed:

1. Estimation of disease burden, cost-of-illness, and meatborne attribution
2. Quantitative microbial risk assessment (QMRA)
3. Costs of the interventions
4. Acceptance by consumers (DCE)
5. Estimation of producer and consumer changes due to new prices
6. Cost and benefits for the stakeholders involved: government, consumers, farmers, freezing meat companies, and slaughterhouses



# Model





## Stakeholders involved with the interventions

- Consumers:      Improvement of quality of life  
Decline of patient cost  
Less productivity losses  
Meat consumption will change, consumer surplus
- Producers:      Farmers, higher costs for biosecurity interventions  
Freezing meat companies, freezing costs ->consumers  
Slaughterhouses, serology and audit cost->consumers
- Government:    Less healthcare costs  
Less special education costs



## QMRA meatborne toxoplasmosis: insight in risky products

| Species                  | QMRA 2011   | QMRA 2018   |
|--------------------------|-------------|-------------|
| Beef                     | <b>67.6</b> | <b>84.0</b> |
| Lamb & Mutton            | 14.0        | 0.2 & 3.7   |
| Pork                     | 11.2        | 12.0        |
| <b>Products</b>          |             |             |
| Filet américain          | <b>37.8</b> | <b>79.8</b> |
| Pork sausage (theeworst) | 0.2         | 10.3        |
| Leg of mutton            | 1.0         | 3.7         |



## Discrete choice experiment (DCE)

### Aim:

- To gather information on consumers' change in willingness to pay for frozen meat

### DCE:

- Technique to elicit preferences of respondents
- By presenting choices to respondent of service or product of interest
- Based on systematic variation of relevant characteristics

### Results:

- Most consumers are not willing to pay more for frozen meat, regardless the increase in food safety.
- People trust that food sold in NL is safe



## Economic evaluation

- All available input and output from the models are collected in an Excel model
- The net value is assessed by comparing the reference scenario (current situation with no additional measures) with the two interventions including reduced *Toxoplasma* transmission
- Based on the input parameters, net results are presented in a range with the least and most favourable outcomes
- Price level 2016



## Annual costs and benefits freezing meat intervention \* €1000

|                         | Steak tartare |        | Beef steak |      | Lamb chop |      | Leg of mutton |       |
|-------------------------|---------------|--------|------------|------|-----------|------|---------------|-------|
| Stakeholders            | Min           | Max    | Min        | Max  | min       | max  | min           | max   |
| Freezing companies      | -975          | -89    | -4,811     | -626 | -98       | -8   | -28           | -8    |
|                         | +975          | +89    | +4,811     | +626 | +98       | +8   | +28           | +8    |
| Consumers               |               |        |            |      |           |      |               |       |
| Freezing costs          | -975          | -89    | -4,811     | -626 | -98       | -8   | -28           | -8    |
| DALYs averted           | 10,408        | 15,612 | 190        | 286  | 5.3       | 8    | 487           | 730   |
| Patient costs           | 12            | 24     | 0.2        | 0.4  | 0.0       | 0.0  | 0.6           | 1.1   |
| Productivity losses     | 199           | 362    | 3.6        | 6.6  | 0.1       | 0.2  | 9             | 17    |
| Consumer surplus        | -907          | -112   | -2,722     | -622 | -10       | -8   | -4            | -3    |
| Government              |               |        |            |      |           |      |               |       |
| Healthcare costs        | 1,836         | 15,136 | 33.6       | 277  | 0.9       | 7.8  | 86            | 708   |
| Special education costs | 3.2           | 143.3  | 0.06       | 2.6  | 0.0       | 0.1  | 0.2           | 6.7   |
| Net benefits            | 10,576        | 31,077 | -7305      | -625 | -102      | -0.6 | 550           | 1,452 |



## Annual costs and benefits biosecurity intervention \* €1000

| Stakeholders                         | Biosecurity intervention |               |
|--------------------------------------|--------------------------|---------------|
|                                      | Min                      | Max           |
| Farmers                              | <b>-2,103</b>            | <b>-701</b>   |
| Slaughterhouses                      | -439                     | -482          |
|                                      | +439                     | +482          |
| Consumers                            |                          |               |
| - Intervention costs slaughterhouses | <b>-439</b>              | <b>-482</b>   |
| - DALYs averted                      | <b>16</b>                | <b>23</b>     |
| - Patient costs                      | 0.02                     | 0.04          |
| - Productivity losses                | 0.3                      | 0.5           |
| Government                           |                          |               |
| - Healthcare costs                   | 3                        | 23            |
| - Special education costs            | 0.006                    | 0.2           |
| Net costs/benefits                   | <b>-2,525</b>            | <b>-1,136</b> |





## To conclude

- Freezing meat is more effective than enhancing biosecurity to prevent toxoplasmosis
- A low effectiveness of biosecurity intervention was assumed, only 1%. Possibly in future results can be adjusted in a positive way
- Freezing filet américain and leg of mutton result in net benefits to society
- Surprisingly, consumers are *not* intended to buy industrially frozen (and thawed) meat



# Publications

PLOS ONE

Received: 28 April 2017  
DOI: 10.1111/zph.12417

ORIGINAL ARTICLE

WILEY

## The design of a Social Cost-Benefit Analysis of preventive interventions for toxoplasmosis: An example of the One Health approach

A. W. M. Suijkerbuijk<sup>1</sup> | P. F. van Gils<sup>1</sup> | A. A. Bonačić Marinović<sup>2</sup> | T. L. Feenstra<sup>1,3</sup> | L. M. Kortbeek<sup>2</sup> | M.-J. J. Mangen<sup>2</sup> | M. Opsteegh<sup>2</sup> | G. A. de Wit<sup>1,4</sup> | J. W. B. van der Giessen<sup>2</sup>

RESEARCH ARTICLE

## A social cost-benefit analysis of two One Health interventions to prevent toxoplasmosis

Anita W. M. Suijkerbuijk<sup>1\*</sup>, Eelco A. B. Over<sup>1</sup>, Marieke Opsteegh<sup>1</sup>, Huifang Deng<sup>1</sup>, Paul F. van Gils<sup>1</sup>, Axel A. Bonačić Marinović<sup>1</sup>, Mattijs Lambooi<sup>1</sup>, Johan J. Polder<sup>1,2</sup>, Talitha L. Feenstra<sup>1,3</sup>, Joke W. B. van der Giessen<sup>1</sup>, G. Ardine de Wit<sup>1,4</sup>, Marie-Josée J. Mangen<sup>1</sup>

**1** National Institute for Public Health and the Environment, Bilthoven, the Netherlands, **2** Tilburg University, Tranzo, School of Social and Behavioral Sciences, Tilburg, the Netherlands, **3** University of Groningen, Department of epidemiology, Groningen, the Netherlands, **4** University Medical Center Utrecht, Julius Center for Health Sciences and Primary Care, Utrecht, the Netherlands

\* [anita.suijkerbuijk@rivm.nl](mailto:anita.suijkerbuijk@rivm.nl)

Abstract



Contents lists available at ScienceDirect

Meat Science

journal homepage: [www.elsevier.com/locate/meatsci](http://www.elsevier.com/locate/meatsci)



## Consumers' preferences for freezing of meat to prevent toxoplasmosis—A stated preference approach

Mattijs S. Lambooi<sup>1,a</sup>, Jorien Veldwijk<sup>1,b</sup>, Paul van Gils<sup>2</sup>, Marie-Josée J. Mangen<sup>2</sup>, Eelco Over<sup>2</sup>, Anita Suijkerbuijk<sup>2</sup>, Johan Polder<sup>2,c</sup>, G. Ardine de Wit<sup>2,d</sup>, Marieke Opsteegh<sup>2</sup>

<sup>a</sup> National Institute for Public Health and the Environment, RIVM, Bilthoven, The Netherlands  
<sup>b</sup> Erasmus School of Health Policy & Management (ESHPM), Erasmus Choice Modelling Center (SCMC), Erasmus University, The Netherlands  
<sup>c</sup> Tilburg University, Tranzo, School of Social and Behavioral Sciences, Tilburg, The Netherlands  
<sup>d</sup> University Medical Center Utrecht, the Netherlands, Julius Center for Health Sciences and Primary Care, The Netherlands





# Media attention.....

**de Volkskrant**

tergrond Columns & Opinie Video Wetenschap Mensen De Gids Cultuur

**NIEUWS RAUW VLEES**

## RIVM: invriezen filet americain scheelt honderden ziektegevallen

Het invriezen van filet americain kan een infectieziekte voorkomen die jaarlijks bij honderden Nederlanders leidt tot ernstige gezondheidsproblemen. Dat stelt het Rijksinstituut voor Volksgezondheid en Milieu (RIVM) in een studie die is gepubliceerd in het tijdschrift *Plos One*.

**RTLnieuws** RTL Nieuws Tip ons

Nieuws Economie Sport Entertainment Tech Lifestyle EditieNL Uitzendingen

## Filet americain en tartaar invriezen, of gewoon niet meer eten?

15 mei 2019 13:30  
Aangepast: 15 mei 2019 16:23



**NOS** @NOS Volgen

### RIVM: filet americain moet je invriezen, anders kans op hersenafwijking



**RIVM: filet americain invriezen, dan daalt aantal medische afwijkingen**  
In het vleesproduct kan een bacterie zitten die bij ongeboren kinderen hersen- en oogafwijkingen kan veroorzaken.

nos.nl



## Relevance for other countries?





# Danke für Ihre Aufmerksamkeit!

And many thanks to all colleagues who collaborated in this project:

Axel Bonačić Marinović

Jenny Deng

Talitha Feenstra

Joke van der Giessen

Paul van Gils

Titia Kortbeek

Mattijs Lambooij

Marie-Josee Mangen

Marieke Opsteegh

Eelco Over

Johan Polder

Ardine de Wit